These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9419454)

  • 41. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
    Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
    Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
    Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
    Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia.
    Sato N; Narita M; Takahashi M; Yagisawa K; Liu A; Abe T; Nikkuni K; Furukawa T; Toba K; Aizawa Y
    Hematol Oncol; 2003 Jun; 21(2):67-75. PubMed ID: 12802811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
    Valent P; Sadovnik I; Eisenwort G; Bauer K; Herrmann H; Gleixner KV; Schulenburg A; Rabitsch W; Sperr WR; Wolf D
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31470642
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer.
    Zha X; Xu L; Chen S; Yang L; Zhang Y; Lu Y; Yu Z; Li B; Wu X; Zheng W; Li Y
    Oncotarget; 2016 Dec; 7(51):84246-84257. PubMed ID: 27713165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transgenic interleukin 2 secreted by CML dendritic cells stimulates autologous T(H)1 T cells.
    Dietz AB; Litzow MR; Bulur PA; Vuk-Pavlović S
    Cytotherapy; 2001; 3(2):97-105. PubMed ID: 12028832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
    Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
    Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
    Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
    J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
    Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
    Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells.
    Tong XM; Yao HP; Qian WB; Zhu LF; Fu ZH; Huang ZL; Jin J
    Int J Lab Hematol; 2008 Oct; 30(5):372-81. PubMed ID: 18205840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
    Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells.
    Monma F; Nishii K; Ezuki S; Miyazaki T; Yamamori S; Usui E; Sugimoto Y; Lorenzo V F; Katayama N; Shiku H
    Cancer Genet Cytogenet; 2006 Jan; 164(2):118-21. PubMed ID: 16434313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.
    Zha X; Chen S; Yang L; Li B; Chen Y; Yan X; Li Y
    Hum Immunol; 2011 Oct; 72(10):798-804. PubMed ID: 21820025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
    Eisendle K; Wolf D; Gastl G; Kircher-Eibl B
    Leuk Lymphoma; 2005 May; 46(5):663-70. PubMed ID: 16019503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.
    Rusakiewicz S; Madrigal A; Travers P; Dodi AI
    Cancer Immunol Immunother; 2009 Sep; 58(9):1449-57. PubMed ID: 19360407
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
    Schwartz J; Pinilla-Ibarz J; Yuan RR; Scheinberg DA
    Semin Hematol; 2003 Jan; 40(1):87-96. PubMed ID: 12563615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
    Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
    J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.